Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open‐label, cross‐over trial

Comparison of Treatment with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycaemia (HypoDeg): A Prospective, Randomized, Open-Label, Crossover Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3690928 ◽

2020 ◽

Author(s):

Rikke Agesen ◽

Amra Ciric Alibegovic ◽

Henrik Ullits Andersen ◽

Henning Beck-Nielsen ◽

Peter Gustenhoff ◽

...

Keyword(s):

Type 1 Diabetes ◽

Crossover Trial ◽

Severe Hypoglycaemia ◽

Insulin Degludec ◽

Open Label

Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(18)30297-6 ◽

2018 ◽

Vol 391 (10128) ◽

pp. 1367-1377 ◽

Cited By ~ 141

Author(s):

Lutz Heinemann ◽

Guido Freckmann ◽

Dominic Ehrmann ◽

Gabriele Faber-Heinemann ◽

Stefania Guerra ◽

...

Keyword(s):

Type 1 Diabetes ◽

Randomised Controlled Trial ◽

Severe Hypoglycaemia ◽

Controlled Trial ◽

Glucose Monitoring ◽

Randomised Controlled ◽

Multiple Daily Insulin Injections ◽

Impaired Hypoglycaemia Awareness ◽

Hypoglycaemia Awareness

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(12)60204-9 ◽

2012 ◽

Vol 379 (9825) ◽

pp. 1489-1497 ◽

Cited By ~ 221

Author(s):

Simon Heller ◽

John Buse ◽

Miles Fisher ◽

Satish Garg ◽

Michel Marre ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Open Label ◽

Phase 3 ◽

Mealtime Insulin ◽

Basal Bolus

Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.

Endocrine Practice ◽

10.1016/j.eprac.2021.11.001 ◽

2021 ◽

Author(s):

Wendy S. Lane ◽

Stephen L. Weinrib ◽

Michael J. Lawrence ◽

Benjamin C. Lane ◽

Ryan T. Jarrett

Keyword(s):

Type 1 Diabetes ◽

Glycemic Control ◽

Basal Insulin ◽

Crossover Trial ◽

Insulin Pump ◽

Insulin Degludec ◽

Single Center ◽

Open Label ◽

Randomized Crossover Trial

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30150-0 ◽

2019 ◽

Vol 7 (6) ◽

pp. 462-472 ◽

Cited By ~ 21

Author(s):

Emanuele Bosi ◽

Pratik Choudhary ◽

Harold W de Valk ◽

Sandrine Lablanche ◽

Javier Castañeda ◽

...

Keyword(s):

Type 1 Diabetes ◽

Randomised Controlled Trial ◽

Insulin Pump ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Randomised Controlled

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders ◽

10.1186/s12902-019-0408-x ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 1

Author(s):

Rikke Mette Agesen ◽

Amra Ciric Alibegovic ◽

Henrik Ullits Andersen ◽

Henning Beck-Nielsen ◽

Peter Gustenhoff ◽

...

Keyword(s):

Type 1 Diabetes ◽

High Risk ◽

Severe Hypoglycaemia ◽

Insulin Degludec ◽

Nocturnal Hypoglycaemia

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

Diabetes Care ◽

10.2337/dc11-2503 ◽

2012 ◽

Vol 35 (11) ◽

pp. 2174-2181 ◽

Cited By ~ 49

Author(s):

I. B. Hirsch ◽

B. Bode ◽

J.-P. Courreges ◽

P. Dykiel ◽

E. Franek ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Target Trial ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Basal Bolus

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12298 ◽

2014 ◽

Vol 16 (10) ◽

pp. 922-930 ◽

Cited By ~ 29

Author(s):

M. J. Davies ◽

J. L. Gross ◽

Y. Ono ◽

T. Sasaki ◽

G. Bantwal ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Aspart ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Open Label ◽

Mealtime Insulin ◽

Basal Bolus

Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(18)30078-0 ◽

2018 ◽

Vol 6 (7) ◽

pp. 527-537 ◽

Cited By ~ 40

Author(s):

Sandrine Lablanche ◽

Marie-Christine Vantyghem ◽

Laurence Kessler ◽

Anne Wojtusciszyn ◽

Sophie Borot ◽

...

Keyword(s):

Type 1 Diabetes ◽

Kidney Transplantation ◽

Randomised Controlled Trial ◽

Insulin Therapy ◽

Islet Transplantation ◽

Severe Hypoglycaemia ◽

Controlled Trial ◽

Randomised Controlled

Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial

The Lancet Digital Health ◽

10.1016/s2589-7500(19)30003-2 ◽

2019 ◽

Vol 1 (1) ◽

pp. e17-e25 ◽

Cited By ~ 35

Author(s):

Pierre-Yves Benhamou ◽

Sylvia Franc ◽

Yves Reznik ◽

Charles Thivolet ◽

Pauline Schaepelynck ◽

...

Keyword(s):

Type 1 Diabetes ◽

Closed Loop ◽

Crossover Trial ◽

Real Life ◽

Insulin Delivery ◽

Open Label ◽

Life Conditions ◽

Randomised Controlled